Sign In
Buy BLUE
$4.97
+0 (+0%)
At Close: Aug 29, 2025
Bristol Myers, bluebird Submit BLA for Myeloma Drug to FDA
03:50pm, Wednesday, 01'st Apr 2020
Bristol Myers (BMY) and bluebird file a biologics license application to the FDA seeking approval of idecabtagene vicleucel for heavily pre-treated patients with multiple myeloma. Stock gains.
BMS, bluebird file for approval of CAR-T cell therapy for multiple myeloma
02:26pm, Wednesday, 01'st Apr 2020
The submission of an application for idecabtagene vicleucel comes shortly after Bristol-Myers Squibb filed for approval of another CAR-T, lisocabtagene maraleucel, in an aggressive form of lymphoma. T
So Your Biotech Announced Positive Phase 3 Results? Celebrating Could be Premature
10:51am, Wednesday, 01'st Apr 2020
Success in clinical trials doesn't guarantee success on the market.
BMS’ big merger bet is still on with latest CAR-T filing
09:39am, Wednesday, 01'st Apr 2020
Bristol-Myers Squibb and development partner bluebird bio have filed their multiple myeloma CAR-T with the FDA, the final part of a three-drug bet with shareholders that was a sweetener following its
Bristol Myers, bluebird Submit BLA for Myeloma Drug to FDA
12:00am, Wednesday, 01'st Apr 2020BRIEF-Bristol Myers Squibb Says BLA Submission Includes Results From Pivotal Phase 2 Karmma Study
11:47am, Tuesday, 31'st Mar 2020
Bristol-Myers Squibb Co:
Celgene CVR holders near finish line with bb2121 filing in U.S.
11:40am, Tuesday, 31'st Mar 2020
Bristol-Myers Squibb (NYSE:BMY) and collaboration partner bluebird bio (NASDAQ:BLUE) announce the filing of a U.S. marketing application for idecabtagene vicleucel (bb2121) for the treatment of adult
Bristol-Myers, Bluebird Bio submit BLA to FDA for for idecabtagene vicleucel BMY;BLUE
11:13am, Tuesday, 31'st Mar 2020
Bristol-Myers, Bluebird Bio submit BLA to FDA for for idecabtagene vicleucel BMY BLUE
Bristol Myers Squibb & bluebird bio Announce Submission of BLA for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) to FDA
What You Need To Know About The bluebird bio, Inc. (NASDAQ:BLUE) Analyst Downgrade Today
10:51am, Tuesday, 31'st Mar 2020
Market forces rained on the parade of bluebird bio, Inc. (NASDAQ:BLUE) shareholders today, when the analysts...
bluebird bio (NASDAQ:BLUE) Price Target Cut to $107.00
08:32am, Tuesday, 31'st Mar 2020
bluebird bio (NASDAQ:BLUE) had its target price lowered by BMO Capital Markets from $132.00 to $107.00 in a research note released on Friday morning, The Fly reports. The brokerage currently has an ou
William Blair Reaffirms Hold Rating for bluebird bio (NASDAQ:BLUE)
08:32am, Tuesday, 31'st Mar 2020
William Blair reiterated their hold rating on shares of bluebird bio (NASDAQ:BLUE) in a research note issued to investors on Friday morning, AnalystRatings.com reports. A number of other analysts have
Cell and gene therapy firm raises $170M investment
03:35pm, Monday, 30'th Mar 2020
ElevateBio CEO David Hallal.
bluebird bio Inc (NASDAQ:BLUE) Shares Sold by Capital Bank & Trust Co
10:34am, Sunday, 29'th Mar 2020
Capital Bank & Trust Co lowered its position in shares of bluebird bio Inc (NASDAQ:BLUE) by 99.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned
